{
    "clinical_study": {
        "@rank": "36651", 
        "acronym": "B-R-ENDA", 
        "arm_group": {
            "arm_group_label": "Bendamustine and subcutaneous Rituximab", 
            "arm_group_type": "Experimental", 
            "description": "single-arm non randomized"
        }, 
        "brief_summary": {
            "textblock": "Bendamustine is a well tolerable and very active agent in the treatment of Non Hodgkin's\n      lymphoma. However, in particular in aggressive B-cell lymphoma, only very few, small studies\n      have investigated the role of bendamustine in the treatment algorithm. The aim of the\n      current B-R-ENDA trial is to investigate efficacy and toxicity of the combination treatment\n      of bendamustine and subcutaneous rituximab in old patients or in elderly patients with high\n      comorbidity who do not qualify for a CHOP like treatment. The results of this study will\n      form the basis of a larger, prospective randomized phase III trial."
        }, 
        "brief_title": "Rituximab and Bendamustine in Very Elderly Patients or Elderly Medically Non Fit Patients With Aggressive B-cell Lymphoma", 
        "completion_date": {
            "#text": "October 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Aggressive Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Aggression", 
                "Lymphoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "Bendamustine is a well tolerable and very active agent in the treatment of Non Hodgkin's\n      lymphoma. However, in particular in aggressive B-cell lymphoma, only very few, small studies\n      have investigated the role of bendamustine in the treatment algorithm. The aim of the\n      current B-R-ENDA trial is to investigate efficacy and toxicity of the combination treatment\n      of bendamustine and subcutaneous rituximab in old patients or in elderly patients with high\n      comorbidity who do not qualify for a CHOP like treatment. The results of this study will\n      form the basis of a larger, prospective randomized phase III trial."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histology: Diagnosis of aggressive CD20+, confirmed by an excisional biopsy of a\n             lymph node or by a sufficiently extensive biopsy of an extranodal involvement if\n             there is no lymph node involvement. It will be possible to treat the following\n             entities in this study as defined by the new WHO classification of 2008: B-NHL,\n             Follicular lymphoma grade IIIb,DLBCL, not otherwise specified (NOS),common\n             morphologic variants: centroblastic,immunoblastic,anaplastic,rare morphologic\n             variants.DLBCL subtypes/entities:T cell/histiocyte rich large B-cell lymphoma,\n             primary cutaneous DLBCL, leg type, EBV-positive DLBCL of the elderly, DLBCL\n             associated with chronic inflammation, primary mediastinal (thymic) large B-cell\n             lymphoma, intravascular large B-cell lymphoma,ALK-positive large B-cell lymphoma,\n             Plasmoblastic lymphoma, Primary effusion lymphoma, B-cell lymphoma, unclassifiable,\n             with features inter\u00acmediate between diffuse large B-cell lymphoma and Burkitt\n             lymphoma, B-cell lymphoma, unclassifiable, with features inter\u00acmediate between\n             diffuse large B-cell lymphoma and Hodgkin lymphoma\n\n          -  Stage: Any stages according to Ann Arbor Classification\n\n          -  Risk group: All risk groups (IPI 1 to 5)\n\n          -  Life expectancy Life expectancy of at least 6 weeks, when lymphoma is treated\n\n          -  Age: Age elder than 81 or Age 61 to 80 and CIRS >6 not qualifying for CHOP-therapy\n\n          -  Gender: any\n\n          -  Performance status: Performance status ECOG 0 - 3. The performance status of each\n             patient is to be assessed at the time of registration which might be after the\n             initiation of pre-phase treatment which, as experience has shown, can result in a\n             significant improvement of the patient\u00b4s performance status. A definition of the\n             performance status is provided in Appendix 25.6\n\n          -  Ability to give informed consent\n\n          -  Written informed consent of the patient\n\n          -  Contract of participation signed by the study center and sponsor\n\n        Exclusion Criteria:\n\n          -  Already initiated lymphoma therapy (except for the prephase treatment until first\n             application of rituximab)\n\n          -  Serious accompanying disorder or impaired organ function (except when due to lymphoma\n             involvement), in particular: Heart: angina pectoris CCS >2, cardiac failure NYHA >3;\n             Lungs: the patient is to be excluded if the resultant pulmonary function test shows\n             FEV1<50% or a diffusion capacity <50% of the reference values: Calculated creatinin\n             clearance < 10 ml/min (Cockcroft-Gault); Liver: total bilirubin > 3 mg/dl;\n             Uncontrollable diabetes mellitus (because of prephase treatment with prednisone!)\n\n          -  Platelets <100 000/mm3, leukocytes <2500/mm3 (if not due to lymphoma)\n\n          -  Known hypersensitivity to the medications to be used\n\n          -  HIV-positivity\n\n          -  Acute or chronic active hepatitis\n\n          -  Poor patient compliance\n\n          -  Simultaneous participation in other treatment studies\n\n          -  Prior chemo- or radiotherapy, long-term use of corticosteroids or anti-neoplastic\n             drugs for previous disorder\n\n          -  Other concomitant tumor disease and/or tumor disease in the past 5 years (except\n             basalioma of the skin and carcinoma in situ)\n\n          -  CNS involvement of lymphoma (intracerebral, meningeal, intraspinal)\n\n          -  Active serious infections not controlled by oral or intravenous antibiotics or\n             anti-fungal\n\n          -  Any medical condition which in the opinion of the investigator places the subject at\n             an unacceptably high risk for toxicities.\n\n          -  Non-conformity to eligibility criteria."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "60 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 30, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01686321", 
            "org_study_id": "DSHNHL-2010-1", 
            "secondary_id": "2010-024004-98"
        }, 
        "intervention": {
            "arm_group_label": "Bendamustine and subcutaneous Rituximab", 
            "intervention_name": "Bendamustine and subcutaneous rituximab", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Bendamustine", 
                "Rituximab", 
                "Nitrogen Mustard Compounds"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "elderly patients", 
            "bendamustine"
        ], 
        "lastchanged_date": "February 21, 2013", 
        "location": {
            "contact": {
                "email": "brenda.studie@med.uni-goettingen.de", 
                "last_name": "Elke Stitz", 
                "phone": "+49551398546"
            }, 
            "contact_backup": {
                "email": "brenda.studie@med.uni-goettingen.de", 
                "last_name": "Florian Zettl, MD", 
                "phone": "+49551398546"
            }, 
            "facility": {
                "address": {
                    "city": "G\u00f6ttingen", 
                    "country": "Germany", 
                    "zip": "37075"
                }, 
                "name": "Prof. Tr\u00fcmper"
            }, 
            "investigator": [
                {
                    "last_name": "Lorenz Tr\u00fcmper, Prof. Dr.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Florian Zettl, MD", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "1", 
        "official_title": "Subcutaneous Rituximab and Intravenous Bendamustine in Very Elderly Patients or Elderly Medically Non Fit Patients (\"Slow Go\") With Aggressive CD20-positive B-cell", 
        "overall_contact": {
            "email": "brenda.studie@med.uni-goettingen.de", 
            "last_name": "Florian Zettl, MD", 
            "phone": "+49551398546"
        }, 
        "overall_contact_backup": {
            "email": "brenda.studie@med.uni-goettingen.de", 
            "last_name": "Elke Stitz", 
            "phone": "+49551398546"
        }, 
        "overall_official": {
            "affiliation": "University medicine Goettingen", 
            "last_name": "Lorenz Tr\u00fcmper, Prof", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Paul-Ehrlich-Institut", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "adverse events (AE)'s", 
                "safety_issue": "Yes", 
                "time_frame": "up to 30 days after last study drug administration"
            }, 
            {
                "measure": "serious adverse events (SAE)'s", 
                "safety_issue": "Yes", 
                "time_frame": "up to 30 days after last study drug administration"
            }, 
            {
                "measure": "rate of therapy-associated deaths", 
                "safety_issue": "Yes", 
                "time_frame": "up to 30 days after last study drug administration"
            }, 
            {
                "measure": "protocol adherence", 
                "safety_issue": "No", 
                "time_frame": "18 weeks after start of therapy"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01686321"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of G\u00f6ttingen", 
            "investigator_full_name": "Lorenz, Tr\u00fcmper, MD", 
            "investigator_title": "Prof. Dr.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "CR rate", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "PR rate", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "rate of primary progression", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "relapse rate", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "event-free survival", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "overall survival", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Quality of life", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Comprehensive Geriatric Assessment", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }
        ], 
        "source": "University of G\u00f6ttingen", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Roche Pharma AG", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Mundipharma Research GmbH & Co KG", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "University of G\u00f6ttingen", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}